Wolf H, Iversen H G, Rosenkilde P, Schrøder T
Department of Urology, KK Hvidovre University Hospital, Denmark.
Scand J Urol Nephrol Suppl. 1987;104:127-32.
Ninety-nine primary transitional cell bladder tumours of categories T1 or T2 were treated by transurethral resection. 25% of these patients experienced a true recurrence indicating that surgery failed to control the tumour locally. These patients had a 5-year survival of 20%. We suspect that many of them did not have local disease when treated. Twenty-five % of the total patient population did not within five years get a new tumour. They were cured by the first transurethral resection. 30% of the patients experienced new non-invasive tumour growth that could be managed by repeated resections. These two groups of patients did extremely well, since the 5-year survival was equivalent to the 5-year survival of an age and sex matched control population. Thus, more than 50% of the patients benefitted from transurethral surgery. Less than 20% experienced a new invasive tumour growth. They are patients at risk of getting a progressive bladder cancer disease. 5-year survival of these patients was about 50%. We conclude that transitional cell bladder tumours of category T1 and some of category T2 are well treated by transurethral resection.
99例T1或T2期原发性膀胱移行细胞肿瘤接受了经尿道切除术治疗。这些患者中有25%出现真正的复发，表明手术未能在局部控制肿瘤。这些患者的5年生存率为20%。我们怀疑他们中的许多人在接受治疗时并非局部病变。在全体患者中，有25%在5年内未出现新肿瘤。他们通过首次经尿道切除术得以治愈。30%的患者出现新的非侵袭性肿瘤生长，可通过重复切除进行处理。这两组患者的情况非常好，因为其5年生存率与年龄和性别匹配的对照人群的5年生存率相当。因此，超过50%的患者从经尿道手术中获益。不到20%的患者出现新的侵袭性肿瘤生长。他们是有进展为膀胱癌疾病风险的患者。这些患者的5年生存率约为50%。我们得出结论，T1期以及部分T2期膀胱移行细胞肿瘤通过经尿道切除术可得到良好治疗。
